Currently, there are 11.31M common shares owned by the public and among those 10.62M shares have been available to trade.
The company’s stock has a 5-day price change of 19.16% and -87.51% over the past three months. AEON shares are trading -98.44% year to date (YTD), with the 12-month market performance down to -99.49% lower. It has a 12-month low price of $0.38 and touched a high of $269.28 over the same period. AEON has an average intraday trading volume of 3.16 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.63%, 17.54%, and -98.15% respectively.
Institutional ownership of AEON Biopharma Inc (AMEX: AEON) shares accounts for 14.24% of the company’s 11.31M shares outstanding.
It has a market capitalization of $6.87M and a beta (3y monthly) value of 0.47. The stock’s trailing 12-month PE ratio is 0.00, while the earnings-per-share (ttm) stands at $298.98. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.37% over the week and 5.91% over the month.
Analysts forecast that AEON Biopharma Inc (AEON) will achieve an EPS of -0.35 for the current quarter, -0.35 for the next quarter and 0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.35 while analysts give the company a high EPS estimate of -0.35. Comparatively, EPS for the current quarter was 5.34 a year ago.
Looking at the support for the AEON, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on August 18, 2023, with the firm’s price target at $18.
